CORE--PSYCHOPHARMACOLOGY/BIOMEDICAL RESEARCH

精神药理学/生物医学研究实验室一直是 自1986年成立以来，一直是《儿童权利公约》的重要组成部分。重大发现 包括证明用标准的抑郁症治疗 三环药物仍然有效，即使在最古老和最脆弱的 患者，这些抑郁症与“未能茁壮成长”， 痴呆症的治疗反应与其他疾病不同， 通常用于治疗老年疾病的药物 会引起精神症状它提供了一个持续的基础设施， 使药理学和生物医学研究，通过其行为， 自己的内在研究，促进与CRC的合作研究 科学家和其他人，以及与广泛的 一群调查员和实习生它还积极参与 治疗精神障碍的多中心临床试验 晚年，并致力于发展这些研究。本申请要求 支持实验室继续提供 这条调查线的基础设施。它还要求支持 三个具体的试点研究：1）双盲，安慰剂- 文拉法辛治疗原发性高血压的随机对照临床试验 与骨关节炎相关的抑郁和疼痛。这是一 干预发展研究，旨在提供有关 药物治疗对最常见致残性疾病的价值 并促进我们对治疗相关的 抑郁和疼痛之间的相互作用。2)一项关于艾滋病患病率的研究 皮质下和深层白色物质高信号， 与认知的关联（例如，执行功能）缺陷和 糖尿病患者的快感缺乏或冷漠（非抑郁）。本研究 旨在确定患者是否处于“亚临床” 脑血管疾病”表现出精神症状， （初级或次级）预防性干预措施。3)探索性研究 炎性细胞因子的行为药理学。这些将 包括在健康的年轻成年志愿者中进行的挑战研究， 对伤寒疫苗的主观、行为和生理反应， 老年人肿瘤坏死因子相关性疾病的治疗研究 对手。该研究旨在开发治疗模型 由尼古丁介导的病态行为和抑郁症。

The Laboratory for Psychopharmacological/Biomedical Research has been a key component of the CRC since its inception in 1986. Significant findings have include the demonstration that treatment of depression with standard tricyclic agents remains efficacious even in the oldest and most frail of patients, that those depressions associated with "failure to thrive" and dementia differ in treatment response from other disorders and that medications commonly used for treatment of medical disorders in late life can cause psychiatric symptoms. It provides an ongoing infrastructure to enable pharmacological and biomedical research through the conduct of its own intrinsic research, facilitating collaborative research with CRC scientists and others, and outreach/consultative activities with a wide array of investigators and trainees. It also actively participates in multi-center clinical trials of the treatment of the mental disorders of late life, and works to develop these studies. This application requests support for the Laboratory to continue to provide an enabling infrastructure for this line of investigation. It also requests support for three specific pilot investigations: 1) A double-blind, placebo- controlled, randomized clinical trial of venlafaxine for the treatment of depression and pain associated with osteoarthritis. This is an intervention development study designed to provide information on the value of pharmacological treatment for the most common disabling condition in late life and to advance our understanding of the treatment-relevant interactions between depression and pain. 2) A study of the prevalence of subcortical and deep white matter hyperintensities, and of their association with cognitive (e.g., executive function) deficits and anhedonia or apathy (non-depressed) patients with diabetes. This study is designed to determine whether patients at high risk for "subclinical cerebrovascular disease" exhibit psychiatric symptoms that may targets for (primary or secondary) preventative interventions. 3) Exploratory studies of the behavioral pharmacology of the inflammatory cytokines. These will include challenge studies in healthy young adult volunteers of the subjective, behavioral and physiological responses to typhoid vaccine, and treatment studies in frail elderly patients of Tumor Necrosis Facto antagonists. The research is designed to develop models for the treatment of cytokine-mediated sickness behavior and depression.